NCT00073931View on ClinicalTrials.gov

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

May 31, 2007

Study Completion Date

July 31, 2014

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

5 µg/kg/day subcutaneously

BIOLOGICAL

sargramostim

250µg/m2/d subcutaneously

PROCEDURE

autologous bone marrow transplantation

autologous stem cells given via central catheter

PROCEDURE

peripheral blood stem cell transplantation

autologous stem cells given via central catheter

RADIATION

tositumomab and iodine I 131 tositumomab

given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with \~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)

Trial Locations (1)

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER